| Study | Reason for exclusion |
|---|---|
| Anwar 2017 | Wrong study design ‐ not RCT (editorial) |
| Berti 2017 | Wrong study design ‐ not RCT (non‐systematic review) |
| BIANCA‐SC | Withdrawn prior to enrolment |
| Booth 2002 | Wrong study design ‐ not RCT (letter) |
| Booth 2004 | Wrong study design ‐ not RCT (open‐label, multi‐centre, prospective trial, not randomised); patients in both study subgroups received infliximab |
| Bosch 2007 | Wrong study design ‐ not RCT (systematic review) |
| Cattran 2011 | Wrong intervention ‐ mycophenolate mofetil vs azathioprine, not anti‐cytokine drugs was assessed |
| Eculizumab 2011 | Withdrawn (the study failed to enrol any patient and sponsor wished to stop) |
| Fraser 2016 | Wrong study design ‐ not RCT |
| Guillevin 2005 | Wrong study design ‐ not RCT (editorial) |
| Herrmann 2012 | Wrong study design ‐ not RCT; single arm study |
| Jayne 2015 | Wrong study design ‐ not RCT (non‐systematic review) |
| Kahn 2010 | Wrong study design ‐ not RCT (letter to the editor) |
| Kontkanen 2010 | Wrong study design ‐ not RCT (letter to the editor) |
| Krishna 2017 | Wrong study design ‐ not RCT (non‐systematic review) |
| Lamprecht 2004 | Wrong study design ‐ not RCT (letter) |
| Lamprecht 2005 | Wrong study design ‐ not RCT (letter to the editor) |
| Lau 2011 | Wrong study design ‐ not RCT (case report) |
| Lee 2008 | Wrong study design ‐ not RCT (non‐systematic review) |
| Lutalo 2015 | Wrong study design ‐ not RCT (non‐systematic review) |
| MEPOCHUSS 2006 | Wrong study design, not RCT, single arm study |
| Merkel 2013 | Wrong study design ‐ not RCT (non‐systematic review) |
| Moosig 2011 | Wrong study design ‐ not RCT (clinical trial, phase II, letter) |
| Moosig 2013 | Wrong study design ‐ not RCT (non‐systematic review) |
| Mukhtyar 2011 | Wrong study design ‐ not RCT |
| Mukhtyar 2016 | Wrong study design ‐ not RCT (abstract of recommendation) |
| Murgia 2014 | Wrong study design ‐ not RCT (non‐systematic review) |
| Niles 2017 | Wrong study design ‐ not RCT (prospective, observational safety study) |
| Puéchal 2017 | Wrong study design ‐ not RCT (non‐systematic review) |
| Rhee 2018 | Wrong study design ‐ post hoc analysis |
| Rheumatology Annual Meeting 2013 | Wrong study design ‐ not RCT |
| Rozin 2003 | Wrong study design ‐ not RCT (letter to the editor) |
| Ruppert 2008 | Wrong study design ‐ not RCT (letter to the editor) |
| Saadoun 2016 | Wrong study design ‐ not RCT (editorial) |
| Sakai 2015 | Wrong study design ‐ not RCT (case report) |
| Samson 2013 | Wrong study design ‐ not RCT, mixed participants with eosinophilic granulomatosis with polyangiitis, polyarteritis nodosa and microscopic polyangiitis from prospective studies |
| Samson 2014 | Wrong intervention ‐ intervention included azathioprine versus cyclophosphamide, not anti‐cytokine drugs |
| Scherer 2006 | Wrong study design ‐ not RCT (non‐systematic review) |
| Seror 2010 | Wrong intervention ‐ intervention included methotrexate versus azathioprine, not anti‐cytokine drugs. Results from pre‐randomisation phase of the prospective multicentre randomised open‐label Wegener’s Granulomatosis‐Entretien (WEGENT) trial |
| Silva 2012 | Wrong study design ‐ not RCT |
| Silva 2013 | Wrong study design ‐ not RCT |
| Silva‐Fernandez 2014 | Wrong study design ‐ not RCT (systematic review which include systematic reviews and meta‐analysis, clinical trials, cohort studies, and case series) |
| Singer 2017 | Wrong study design ‐ not RCT (non‐systematic review) |
| Solans 2008 | Wrong study design ‐ not RCT (editorial) |
| Spina 2009 | Wrong study design ‐ not RCT (letter which describes case report) |
| Tanaka 2012 | Wrong study design ‐ not RCT (non‐systematic review) |
| Watts 2010 | Wrong study design ‐ not RCT (preliminary results of randomised, placebo‐controlled trial of rituximab therapy) |
| Westman 2013 | Wrong study design ‐ not RCT (conference abstract of non‐systematic review) |
BIANCA‐SC ‐ A Study of the Efficacy, Safety, and Tolerability of Blisibimod in Addition to Methotrexate During Induction of Remission in Subjects With ANCA‐Associated Small Vessel Vasculitis
MEPOCHUSS ‐ Safety and Efficacy Study of Mepolizumab in Churg Strauss Syndrome
RCT – randomized controlled trial